Long term recombinant interferon alpha treatment in MS with special emphasis to side effects. (Q40666166)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Long term recombinant interferon alpha treatment in MS with special emphasis to side effects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

L Durelli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M R Bongioanni

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

B Ferrero

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

D Imperiale

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

E Verdun

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

A Oggero

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

E Gentile

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M Bergui

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

L Bergamini

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

B Bergamasco

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

1 reference

1 July 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

366-371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100617

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100617

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100617

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100617

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100617

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100617

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100617

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100617

Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100617

10.1177/135245859600100617

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9345419%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference